Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evogene reports revenue growth and strategic collaborations driving future prospects

Evogene's Q1 2024 performance showed revenue growth, decreased losses, and strategic milestones achieved by key subsidiaries.
The company's strengths lie in innovative collaborations, a unique CPB platform, and successful revenue-driving partnerships.
Challenges include financial management, operational execution, and logistical considerations for seed supply.
Opportunities for growth stem from promising future achievements, strategic partnerships, and market differentiation through innovation.

Evogene reports revenue surge and promising developments in key segments

Evogene demonstrated strong revenue growth in the first half of 2024 and made progress in reducing losses, reflecting improving financial performance.
Casterra's expanding market reach and revenue growth opportunities, coupled with Biomica's promising trial results, position Evogene well for future growth.
While facing challenges in achieving profitability and managing cash flow, Evogene's focus on operational efficiency and market expansion presents avenues for sustainable growth.

Evogene reports Q3 revenue decline but anticipates growth opportunities

Evogene's Q3 2024 performance reflected a decline in revenues but improved cost management, with a focus on enhancing cash reserves.
The company's strengths lie in upcoming revenue growth, strategic collaborations, and plans to fortify its financial position.
Challenges include market uncertainties, operational losses, and addressing investor concerns for sustained growth and profitability.
Opportunities exist for Evogene to capitalize on its achievements, explore new avenues, and drive value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REHOVOT, Israel, Jan. 20, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the...

Biomica Announces Participation at the 5th Microbiome Movement Drug Development Europe Conference on January 28-29, 2021 (Virtual Conference)

REHOVOT, Israel, Dec. 23, 2020 /PRNewswire/ -- Canonic Ltd, a company focused on the development of medical cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) announced today that it has signed its first commercial agreement with a licensed medical...

Canonic Announces Signing of First Cultivation Agreement for its Medical Cannabis Varieties

Antero Resources

Magnolia Oil & Gas Corp

New Age Beverages

PlayAGS

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Sizzling Stocks to Buy Trading Under $10 With Massive Upside Potential

Evogene Ltd. (EVGN) CEO Ofer Haviv on Q3 2020 Results - Earnings Call Transcript

REHOVOT, Israel, Nov. 18, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the third quarter ended...

Evogene Reports Third Quarter 2020 Financial Results

REHOVOT, Israel, Nov. 2, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the third...

Evogene Financial Results and Earnings Announcement Schedule for the Third Quarter of 2020

REHOVOT, Israel, Oct. 30, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today announced...

Evogene Prices $12 Million Registered Direct Offering

Despite its recent share price increase, Evogene continues to be undervalued given the sum of parts valuation of its 4 main subsidiaries and $45 million cash position.

Evogene: Hidden Gems Of Computational Predictive Biology: (Part 4 Of 4), Canonic Ltd. (Medical Cannabis)

REHOVOT, Israel, Sept. 9, 2020 /PRNewswire/ -- Evogene Ltd.

Evogene Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

Evogene: Hidden Gems Of Computational Predictive Biology (Part 3 Of 4) - Ag Plenus (Novel Herbicides And Pesticides)

REHOVOT, Israel, Sept. 1, 2020 /PRNewswire/ -- Evogene Ltd.

Evogene Announces $10 Million Equity Led Investment by ARK Investment Management, LLC

Evogene: Hidden Gems Of Computational Predictive Biology, Part 2 Of 4 - Lavie Bio

REHOVOT, Israel, Aug. 19, 2020 /PRNewswire/ -- Evogene Ltd.

Evogene to Present at LD 500 Virtual Conference

Evogene Ltd. has developed a unique Computational Predictive Biology platform, leveraging big data and artificial intelligence to life-science products such as microbes, small molecules and genes.

Evogene: Hidden Gems Of Computational Predictive Biology, Part 1 Of 4 (Biomica, Microbiome Therapeutics)

Evogene Ltd. (EVGN) CEO Ofer Haviv on Q2 2020 Results - Earnings Call Transcript

REHOVOT, Israel, July 29, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading artificial intelligence company targeting to revolutionize life-science product development across several market segments utilizing computational biology, announces today that Ofer.

Evogene to Present at Jefferies Virtual 2020 Industrials Conference

REHOVOT, Israel, July 15, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces today that it will release its financial results for...

Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2020

REHOVOT, Israel, June 3, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its participation in the CRISPR-IL consortium. The...

Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing

Evogene Ltd (EVGN) CEO Ofer Haviv on Q1 2020 Results - Earnings Call Transcript

REHOVOT, Israel, May 26, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the first quarter, ended...

Evogene Reports First Quarter 2020 Financial Results

REHOVOT, Israel, May 20, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces today its rebranding. The new corporate identity...

Evogene Launches Its New Branding to Reflect the Company's Expanded Vision and New Business Model

Evogene's (EVGN) CEO Ofer Haviv on Q4 2019 Results - Earnings Call Transcript

Evogene's (EVGN) CEO Ofer Haviv on Q3 2019 Results - Earnings Call Transcript

Evogene Ltd (EVGN) CEO Ofer Haviv on Q2 2019 Results - Earnings Call Transcript

Bayer AG

Evogene Ltd. (NASDAQ: EVGN) is amending its collaboration with Bayer AG (OTC: BAYRY)'s crop science division to identify genome editing targets for evaluation against a broad range of corn diseases.

News for Evogene Stock (EVGN)